Abstract
The high incidence of tuberculosis (TB) in the world, especially in developing countries, the resurgence of TB in industrialized countries, and the global increase in the prevalence of Mycobacterium avium complex infections in immunocompromised hosts have prompted the quest for novel antimycobacterial drugs. However, the development of such antimicrobial chemotherapeutics is currently making very slow progress even with using the bioinformatics-based methodology for drug design. It thus appears that devising improved administration protocols for clinical treatment against intractable mycobacterial infections using existing chemotherapeutics is more practical than awaiting the development of new antimycobacterial drugs. The potentiation of host immune responses using immunoadjunctive agents, alternatively called host-directed therapeutics (HDTs), may increase the efficacy of antimycobacterial regimens against mycobacteriosis. Particularly, the modulation of host immunity relating to macrophage antimicrobial functions may be beneficial to the immunoadjunctive therapy. This review will deal with the current status and future prospects regarding the development of HDTs useful for the clinical control of intractable mycobacterial infections.
Keywords: Host directed therapeutics, immunoadjunctive agents, mycobacterial infections, Mycobacterium tuberculosis, Mycobacterium avium complex.
Current Pharmaceutical Design
Title:Host-Directed Therapeutics against Mycobacterial Infections
Volume: 23 Issue: 18
Author(s): Haruaki Tomioka*, Chiaki Sano and Yutaka Tatano
Affiliation:
- Department of Basic Medical Science for Nursing, Department of Primary Education, Yasuda Women’s University, Hiroshima, Hiroshima 731-0153,Japan
Keywords: Host directed therapeutics, immunoadjunctive agents, mycobacterial infections, Mycobacterium tuberculosis, Mycobacterium avium complex.
Abstract: The high incidence of tuberculosis (TB) in the world, especially in developing countries, the resurgence of TB in industrialized countries, and the global increase in the prevalence of Mycobacterium avium complex infections in immunocompromised hosts have prompted the quest for novel antimycobacterial drugs. However, the development of such antimicrobial chemotherapeutics is currently making very slow progress even with using the bioinformatics-based methodology for drug design. It thus appears that devising improved administration protocols for clinical treatment against intractable mycobacterial infections using existing chemotherapeutics is more practical than awaiting the development of new antimycobacterial drugs. The potentiation of host immune responses using immunoadjunctive agents, alternatively called host-directed therapeutics (HDTs), may increase the efficacy of antimycobacterial regimens against mycobacteriosis. Particularly, the modulation of host immunity relating to macrophage antimicrobial functions may be beneficial to the immunoadjunctive therapy. This review will deal with the current status and future prospects regarding the development of HDTs useful for the clinical control of intractable mycobacterial infections.
Export Options
About this article
Cite this article as:
Tomioka Haruaki*, Sano Chiaki and Tatano Yutaka, Host-Directed Therapeutics against Mycobacterial Infections, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612822666161202121550
DOI https://dx.doi.org/10.2174/1381612822666161202121550 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Synthesis and Biological Activity of Pyrazolo[4,3-c]heterocyclic Derivatives: A Mini Review
Mini-Reviews in Organic Chemistry Lipids as Activators of Innate Immunity in Peptide Vaccine Delivery
Current Medicinal Chemistry Potential Role of TRP Channels in Cough Hypersensitivity?
Current Respiratory Medicine Reviews The Role of Essential Oils and the Biological Detoxification in the Prevention of Aflatoxin Borne Diseases
Current Topics in Medicinal Chemistry Preface
Current Drug Targets - Infectious Disorders Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes
Current Drug Targets Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Current Pharmaceutical Design Editorial [Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)]
Current Pharmacogenomics and Personalized Medicine Lichen Depsidones as Potential Novel Pharmacologically Active Compounds
Mini-Reviews in Organic Chemistry Quality by Design Approach for Development and Optimization of Rifampicin Loaded Bovine Serum Albumin Nanoparticles and Characterization
Current Drug Delivery Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets Mucosal Delivery of Vaccines: Role of Mucoadhesive/Biodegradable Polymers
Recent Patents on Drug Delivery & Formulation Pantothenate Utilization by Plasmodium as a Target for Antimalarial Chemotherapy
Infectious Disorders - Drug Targets Acylhydrazide Schiff Bases: DPPH Radical and Superoxide Anion Scavengers
Medicinal Chemistry Recent Advancement in Predicting Subcellular Localization of Mycobacterial Protein with Machine Learning Methods
Medicinal Chemistry Fatty Acids in Marine Organisms: In the Pursuit of Bioactive Agents
Current Pharmaceutical Analysis Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued)